{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:17:12Z","timestamp":1783441032414,"version":"3.54.6"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R35 HL161237"],"award-info":[{"award-number":["1R35 HL161237"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL056728-19"],"award-info":[{"award-number":["R01 HL056728-19"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.canlet.2026.218686","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T06:46:59Z","timestamp":1781851619000},"page":"218686","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Oral connexin43\u2013peptide\u2013loaded milk extracellular vesicles mitigate lethal radiation injury while preserving tumour radiosensitivity"],"prefix":"10.1016","volume":"656","author":[{"given":"Spencer R.","family":"Marsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Beard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Bannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1910-0728","authenticated-orcid":false,"given":"Md Ruhul","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel A.","family":"Letteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilektra","family":"Athanasiadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6021-0796","authenticated-orcid":false,"given":"Robert G.","family":"Gourdie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.canlet.2026.218686_bib1","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/nrc1451","article-title":"Radiation oncology: a century of achievements","volume":"4","author":"Bernier","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.canlet.2026.218686_bib2","first-page":"437","article-title":"Radiation therapy-associated toxicity: etiology, management, and prevention","volume":"71","author":"Wang","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2026.218686_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.666776","article-title":"Classes of drugs that mitigate radiation syndromes","volume":"12","author":"Micewicz","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.canlet.2026.218686_bib4","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7150\/ntno.62213","article-title":"Novel protocols for scalable production of high quality purified small extracellular vesicles from bovine milk","volume":"5","author":"Marsh","year":"2021","journal-title":"Nanotheranostics"},{"issue":"1","key":"10.1016\/j.canlet.2026.218686_bib5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13036-024-00470-z","article-title":"Stabilizing milk-derived extracellular vesicles (mEVs) through lyophilization: a novel trehalose and tryptophan formulation for maintaining structure and bioactivity during long-term storage","volume":"19","author":"Dogan","year":"2025","journal-title":"J. Biol. Eng."},{"key":"10.1016\/j.canlet.2026.218686_bib6","first-page":"2025","article-title":"Orally delivered milk-derived nanovesicles loaded with connexin 43 peptides for targeted cardiac ischemia-reperfusion therapy","author":"Marsh","year":"2025","journal-title":"BioRxiv Prepr Serv Biol."},{"issue":"6","key":"10.1016\/j.canlet.2026.218686_bib7","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/HP.0000000000000279","article-title":"Medical countermeasures for radiation exposure and related injuries: characterization of medicines, FDA-approval status and inclusion into the strategic national stockpile","volume":"108","author":"Singh","year":"2015","journal-title":"Health Phys."},{"key":"10.1016\/j.canlet.2026.218686_bib8","doi-asserted-by":"crossref","DOI":"10.1017\/dmp.2025.12","article-title":"Advanced medical countermeasures and devices for use during a radiological or nuclear emergency","volume":"19","author":"DiCarlo","year":"2025","journal-title":"Disaster Med. Public Health Prep."},{"issue":"3","key":"10.1016\/j.canlet.2026.218686_bib9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1667\/RADE-20-00120.1","article-title":"Cutaneous radiation injuries: models, assessment and treatments","volume":"194","author":"DiCarlo","year":"2020","journal-title":"Radiat. Res."},{"issue":"5","key":"10.1016\/j.canlet.2026.218686_bib10","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1021\/acsptsci.4c00120","article-title":"Degradation of the \u03b1-Carboxyl terminus 11 peptide: in vivo and Ex vivo impacts of time, temperature, inhibitors, and gender in rat","volume":"7","author":"Tasdemiroglu","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"12","key":"10.1016\/j.canlet.2026.218686_bib11","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/nrd.2018.138","article-title":"Therapeutic strategies targeting connexins","volume":"17","author":"Laird","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"12","key":"10.1016\/j.canlet.2026.218686_bib12","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1039\/D4ME00072B","article-title":"Multi-site esterification: a tunable, reversible strategy to tailor therapeutic peptides for delivery","volume":"9","author":"Bannon","year":"2024","journal-title":"Mol Syst Des Eng"},{"issue":"1","key":"10.1016\/j.canlet.2026.218686_bib13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1158\/0008-5472.CAN-15-1286","article-title":"Connexin 43 inhibition sensitizes chemoresistant glioblastoma cells to temozolomide","volume":"76","author":"Murphy","year":"2016","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.canlet.2026.218686_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161079","article-title":"Establishment of early endpoints in mouse total-body irradiation model","volume":"11","author":"Koch","year":"2016","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.canlet.2026.218686_bib15","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1002\/ame2.70109","article-title":"Radiation emergency medical countermeasures: current formulary, identified gaps, and future approaches","volume":"8","author":"Ma","year":"2025","journal-title":"Animal Model. Exp. Med."},{"key":"10.1016\/j.canlet.2026.218686_bib16","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fphar.2020.00212","article-title":"Connexin43 hemichannel targeting with TAT-Gap19 alleviates radiation-induced endothelial cell damage","volume":"11","author":"Ramadan","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.canlet.2026.218686_bib17","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s12885-015-1229-6","article-title":"Targeting connexin 43 with \u03b1-connexin carboxyl-terminal (\u03b1CT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for \u03b1CT1","volume":"15","author":"Grek","year":"2015","journal-title":"BMC Cancer"},{"issue":"23","key":"10.1016\/j.canlet.2026.218686_bib18","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1038\/s41388-019-0741-6","article-title":"Connexins in cancer: bridging the gap to the clinic","volume":"38","author":"Aasen","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2026.218686_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2021.670451","article-title":"Effects of alpha-connexin carboxyl-terminal peptide (\u03b1CT1) and Bowman-Birk Protease Inhibitor (BBI) on canine Oral Mucosal Melanoma (OMM) cells","volume":"8","author":"Sato","year":"2021","journal-title":"Front. Vet. Sci."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526004507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526004507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T15:27:22Z","timestamp":1783438042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526004507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":19,"alternative-id":["S0304383526004507"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218686","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral connexin43\u2013peptide\u2013loaded milk extracellular vesicles mitigate lethal radiation injury while preserving tumour radiosensitivity","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218686","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218686"}}